GeneTwin is the exact‑match .com for the emerging category of genomic digital twins — computational mirrors of your DNA that predict drug response, quantify disease risk, and guide precision care before symptoms emerge. One word. One owner. One of the most defensible names in precision medicine.
The full stack of a genomic digital twin — from raw variant calling, through polygenic scoring, to EHR‑integrated clinical decision support. One domain, one category, one name.
Predict drug metabolism, efficacy, and adverse reactions from CYP450 variants, transporters, and drug targets. Right drug, right dose, first time — the core use case every health system already buys.
Aggregate thousands of low‑effect variants into actionable population‑scaled risk. CVD, T2D, breast & prostate cancer, AD, schizophrenia — quantified before the first symptom.
Match patients to optimal therapies via genetic markers across oncology, psychiatry, and cardiology.
Hundreds of recessive disease variants. CF, sickle cell, Tay‑Sachs, SMA — pre‑conception intelligence.
The twin evolves with science. Re‑scored nightly as new gene–drug associations and variant classifications ship.
CPIC and DPWG guideline‑aligned recommendations delivered at the point of care. EHR‑integrated, real‑time pharmacogenomic alerts that prevent adverse drug events before they occur.
Five stages that convert a physical sample into a living digital model — each addressable by the same one‑word name.
Every nucleotide sequenced. Every variant cataloged. 20,000 protein‑coding genes rendered as an interactive computational twin.
3.2 billion base pairs · 20,000 protein‑coding genes · one living computational mirror of your biology.
Per‑chromosome distribution of clinically actionable variants in this twin. 23 chromosomes, 4.5M SNVs, 42 pathogenic calls flagged for review.
Cluster‑view of the most clinically consequential variants surfaced by the twin — colored by domain and sized by Tier‑1 evidence weight.
~7% of patients. Alters codeine, tamoxifen, amitriptyline, atomoxetine, metoprolol. Single most valuable PGx call.
Abacavir hypersensitivity screening is FDA black‑boxed. Near‑universal pretreatment genotyping in HIV care.
Drives PARP‑inhibitor eligibility, mastectomy timing, cascade testing of first‑degree relatives.
Thrombophilia risk changes anticoagulation, contraception choice, and peri‑operative management.
Late‑onset Alzheimer's risk modifier; informs lecanemab eligibility and monitoring intensity.
A rapidly expanding market driven by falling sequencing costs, regulatory momentum, and clinical validation. The name sits upstream of all of it.
Projected precision medicine TAM — sequencing, interpretation, and digital twin platforms combined.
Call accuracy across clinically actionable variants — tested against orthogonal Sanger confirmation.
Actionable pairs in CPIC & DPWG guidelines. 48 carry FDA prescribing information requirements.
Share of adverse drug reactions that carry a genotype‑explainable mechanism — the PGx addressable surface.
The exact‑match .com for a category the whole industry is moving toward. One owner, forever — or the best ten‑year head start money can buy.